• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Precipio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    9/3/25 4:00:34 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email
    false 0001043961 0001043961 2025-09-03 2025-09-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D. C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): September 3, 2025

     

    PRECIPIO, INC.
    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-36439   91-1789357

    (State of Incorporation)

      (Commission File Number)   (I.R.S. Employer Identification No.)

     

    4 Science Park, New Haven, CT 06511

    (Address of principal executive offices) (Zip Code)

     

    (203) 787-7888

    (Registrant's telephone number, including area code)

       

     

     

    Not Applicable
    (Former name, former address and former fiscal year, if changed since last report date)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Ticker symbol(s) Name of each exchange on which
    registered
    Common Stock, $0.01 par value per share PRPO Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

     

    Item 1.02 Termination of a Material Definitive Agreement

     

    As previously disclosed, on April 14, 2023, Precipio, Inc. (the “Company”) entered into that certain Sales Agreement (the “Sales Agreement”) with A.G.P./Alliance Global Partners (“A.G.P.”), pursuant to which the Company could offer and sell through or to AGP, as sales agent, shares of its common stock, par value $0.01 per share (the “Common Stock”), in sales deemed to be an “at the market offering” (as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended). Effective as of September 2, 2025, the Company terminated the Sales Agreement.

     

    Following the termination of the Sales Agreement, the Company may not offer or sell any additional shares of Common Stock under the Sales Agreement. From April 14, 2023 to September 2, 2025, the Company sold 11,847 shares of Common Stock pursuant to the Sales Agreement for net proceeds of $0.1 million, after deducting commissions and offering expenses.

     

    The foregoing description of the Sales Agreement is not complete and is qualified in its entirety by reference to the full text of the Sales Agreement, a copy of which was filed as Exhibit 1.1 to the Company’s 8-K filed with the Securities and Exchange Commission on April 17, 2023, and is incorporated by reference herein.

     

    A copy of the press release announcing termination of the Sales Agreement is filed as Exhibit 99.1 to this Current Report on Form 8-K.

      

    Item 9.01 Financial Statements and Exhibits

     

    (d) Exhibits

     

    99.1 Press Release issued by Precipio, Inc. on September 3, 2025.
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

      

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      PRECIPIO, INC.
       
      By: /s/ Ilan Danieli
      Name:  Ilan Danieli
      Title: Chief Executive Officer

     

    Date: September 3, 2025

     

     

     

    Get the next $PRPO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Precipio Terminates Its ATM

    NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). "Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for capital raises for the Company," said Ilan Danieli, Precipio's CEO. "Management is committed to creating shareholder value, and this termination is one more step in that direction." About Pr

    9/2/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces its Q2-2025 Financial Results

    NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for 2025. "Yet another quarter of revenue growth in both company divisions, along with overall gross margin improvement, has led to an improved cash performance for the Company. With the remaining repayment of the Change Healthcare loan to be completed by the end of the year, and continued strength in both revenue and margin growth, management believes that the Company is on track to end the year as a cash flow positive business, and with a debt-free, strong ba

    8/13/25 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q2-2025 Shareholder Update Call

    NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be accessed via the

    7/31/25 4:30:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    SEC Filings

    View All

    Precipio Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    9/3/25 4:00:34 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    8/18/25 5:01:19 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Precipio Inc.

    10-Q - Precipio, Inc. (0001043961) (Filer)

    8/13/25 4:25:38 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Cossman Jeffrey was granted 710 shares, increasing direct ownership by 5% to 14,743 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    7/18/25 6:28:20 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Andrews Ronald Asbury was granted 676 shares, increasing direct ownership by 5% to 15,228 units (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    7/18/25 4:36:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Cohen David Seth was granted 888 shares, increasing direct ownership by 2% to 52,942 units (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    7/18/25 4:35:45 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sandberg Richard A bought $13,986 worth of shares (1,399 units at $10.00) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/30/25 4:31:15 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sandberg Richard A bought $990 worth of shares (101 units at $9.80) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/28/25 4:37:44 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sandberg Richard A bought $4,665 worth of shares (500 units at $9.33) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/27/25 4:05:45 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Financials

    Live finance-specific insights

    View All

    Precipio Terminates Its ATM

    NEW HAVEN, Conn., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). "Our Company is in a much stronger position today than it was when we entered into this structure. With our elimination of negative cash flow from operations, and our recent increases of our cash balance, we now have confidence that we no longer have to rely on a tool like this for capital raises for the Company," said Ilan Danieli, Precipio's CEO. "Management is committed to creating shareholder value, and this termination is one more step in that direction." About Pr

    9/2/25 10:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces its Q2-2025 Financial Results

    NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), filed its 10-Q report today. The following are the highlights of the Company's financial performance and outlook for 2025. "Yet another quarter of revenue growth in both company divisions, along with overall gross margin improvement, has led to an improved cash performance for the Company. With the remaining repayment of the Change Healthcare loan to be completed by the end of the year, and continued strength in both revenue and margin growth, management believes that the Company is on track to end the year as a cash flow positive business, and with a debt-free, strong ba

    8/13/25 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q2-2025 Shareholder Update Call

    NEW HAVEN, Conn., July 31, 2025 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q2-2025 corporate update call on August 14th, 2025 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 800.717.1738. All callers should ask for the Precipio conference call. Listeners interested in submitting questions in advance should email their questions to [email protected] and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be accessed via the

    7/31/25 4:30:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Precipio Inc.

    SC 13G - Precipio, Inc. (0001043961) (Subject)

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    View All

    Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    3/21/22 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    11/3/21 8:00:00 AM ET
    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    3/3/21 11:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials